<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37539582</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>07</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1672-7347</ISSN><JournalIssue CitedMedium="Print"><Volume>48</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>May</Month><Day>28</Day></PubDate></JournalIssue><Title>Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences</Title><ISOAbbreviation>Zhong Nan Da Xue Xue Bao Yi Xue Ban</ISOAbbreviation></Journal><ArticleTitle>Systemic lupus erythematosus with acquired hemophilia A: A case report and literature review.</ArticleTitle><Pagination><StartPage>789</StartPage><EndPage>794</EndPage><MedlinePgn>789-794</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.11817/j.issn.1672-7347.2023.220440</ELocationID><ELocationID EIdType="pii" ValidYN="Y">1672-7347(2023)05-0789-06</ELocationID><Abstract><AbstractText>Systemic lupus erythematosus (SLE) complicated with acquired hemophilia A (AHA) is a rare condition with frequently delayed diagnosis and a high mortality rate, so it is necessary to strengthen the understanding of this disease. In this study, the characteristics and treatment in 1 case of SLE complicated by AHA is reported and analyzed, and a literature review is conducted. The patient was a 29-year-old young female with a 10-year history of SLE, the main clinical manifestation was severe abdominal bleeding. Laboratory tests revealed that the activated partial thromboplastin time (APTT) was notably prolonged (118.20 s), and the coagulation factor VIII activity (FVIII&#xa789;C) was extremely decreased (0.20%) with high-titer of factor VIII (FVIII) inhibitor (31.2 BU/mL). After treating with high-dose glucocorticoid, immunoglobulin, cyclophosphamide, rituximab, blood transfusion, and intravenous infusion of human coagulation FVIII, the coagulation function and coagulation FVIII&#xa789;C were improved, and FVIII inhibitor was negative without serious adverse reactions. During the next 5-year follow-up, the patient's condition was stable and no bleeding occurred. In the case of coagulation dysfunction in SLE, especially with isolated APTT prolongation, AHA should be screened. When the therapeutic effects of glucocorticoid combined with immunosuppressants are not desirable, rituximab could be introduced.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Mei</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, First Affiliated Hospital of Shantou University Medical College, Shantou Guangdong 515041. yzaleaf@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Ruiying</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, First Affiliated Hospital of Shantou University Medical College, Shantou Guangdong 515041.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Fengcai</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, First Affiliated Hospital of Shantou University Medical College, Shantou Guangdong 515041.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Research Center, First Affiliated Hospital of Shantou University Medical College, Shantou Guangdong 515041, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hou</LastName><ForeName>Zhiduo</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, First Affiliated Hospital of Shantou University Medical College, Shantou Guangdong 515041. houzhiduo@foxmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Research Center, First Affiliated Hospital of Shantou University Medical College, Shantou Guangdong 515041, China. houzhiduo@foxmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Ling</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, First Affiliated Hospital of Shantou University Medical College, Shantou Guangdong 515041.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Research Center, First Affiliated Hospital of Shantou University Medical College, Shantou Guangdong 515041, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>chi</Language><GrantList CompleteYN="Y"><Grant><GrantID>A2018104</GrantID><Agency>the Medical Scientific Research Foundation of Guangdong Province</Agency><Country/></Grant><Grant><GrantID>2014110109</GrantID><Agency>the Medical Science and Technology Planning Project of Shantou City (&#x3014;2022&#x3015;88), and the Shantou University Medical College Clinical Research Enhancement Initiative</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>1&#x4f8b;&#x7cfb;&#x7edf;&#x6027;&#x7ea2;&#x6591;&#x72fc;&#x75ae;&#x5408;&#x5e76;&#x83b7;&#x5f97;&#x6027;&#x8840;&#x53cb;&#x75c5;A&#x53ca;&#x6587;&#x732e;&#x590d;&#x4e60;.</VernacularTitle></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Zhong Nan Da Xue Xue Bao Yi Xue Ban</MedlineTA><NlmUniqueID>101230586</NlmUniqueID><ISSNLinking>1672-7347</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>4F4X42SYQ6</RegistryNumber><NameOfSubstance UI="D000069283">Rituximab</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>9001-27-8</RegistryNumber><NameOfSubstance UI="D005169">Factor VIII</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C536392">Factor 8 deficiency, acquired</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006467" MajorTopicYN="Y">Hemophilia A</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069283" MajorTopicYN="N">Rituximab</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005169" MajorTopicYN="N">Factor VIII</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="chi"><AbstractText>&#x7cfb;&#x7edf;&#x6027;&#x7ea2;&#x6591;&#x72fc;&#x75ae;(systemic lupus erythematosus&#xff0c;SLE)&#x5408;&#x5e76;&#x83b7;&#x5f97;&#x6027;&#x8840;&#x53cb;&#x75c5;A(acquired hemophilia A&#xff0c;AHA)&#x7f55;&#x89c1;&#xff0c;&#x5bb9;&#x6613;&#x5ef6;&#x8bef;&#x8bca;&#x65ad;&#xff0c;&#x4e14;&#x75c5;&#x6b7b;&#x7387;&#x9ad8;&#xff0c;&#x6709;&#x5fc5;&#x8981;&#x8fdb;&#x4e00;&#x6b65;&#x52a0;&#x6df1;&#x5bf9;&#x8be5;&#x75be;&#x75c5;&#x7684;&#x8ba4;&#x8bc6;&#x3002;&#x672c;&#x6587;&#x62a5;&#x9053;1&#x4f8b;SLE&#x5408;&#x5e76;AHA&#x60a3;&#x8005;&#x7684;&#x75c5;&#x4f8b;&#x7279;&#x70b9;&#x53ca;&#x6cbb;&#x7597;&#x65b9;&#x6cd5;&#xff0c;&#x5e76;&#x8fdb;&#x884c;&#x6587;&#x732e;&#x590d;&#x4e60;&#x3002;&#x60a3;&#x8005;&#x4e3a;29&#x5c81;&#x9752;&#x5e74;&#x5973;&#x6027;&#xff0c;SLE&#x75c5;&#x7a0b;10&#x5e74;&#xff0c;&#x4ee5;&#x8179;&#x8154;&#x5927;&#x51fa;&#x8840;&#x4e3a;&#x4e3b;&#x8981;&#x4e34;&#x5e8a;&#x8868;&#x73b0;&#xff0c;&#x5b9e;&#x9a8c;&#x5ba4;&#x68c0;&#x67e5;&#x6d3b;&#x5316;&#x90e8;&#x5206;&#x51dd;&#x8840;&#x6d3b;&#x9176;&#x65f6;&#x95f4;(activated partial thromboplastin time&#xff0c;APTT)&#x660e;&#x663e;&#x5ef6;&#x957f;(118.20 s)&#xff0c;&#x8840;&#x6d46;VIII&#x56e0;&#x5b50;&#x6d3b;&#x6027;(coagulation factor VIII activity&#xff0c;FVIII&#xa789;C)&#x6781;&#x5ea6;&#x964d;&#x4f4e;(0.20%)&#xff0c;&#x53ef;&#x68c0;&#x6d4b;&#x5230;&#x9ad8;&#x6ef4;&#x5ea6;&#x6297;&#x56e0;&#x5b50;VIII(factor VIII&#xff0c;FVIII)&#x6291;&#x5236;&#x7269; (31.2 BU/mL)&#x3002;&#x4e88;&#x5927;&#x5242;&#x91cf;&#x7cd6;&#x76ae;&#x8d28;&#x6fc0;&#x7d20;&#x3001;&#x5927;&#x5242;&#x91cf;&#x514d;&#x75ab;&#x7403;&#x86cb;&#x767d;&#x3001;&#x73af;&#x78f7;&#x9170;&#x80fa;&#x3001;&#x5229;&#x59a5;&#x6614;&#x5355;&#x6297;&#x53ca;&#x8f93;&#x8840;&#x3001;&#x8865;&#x5145;&#x4eba;&#x51dd;&#x8840;&#x56e0;&#x5b50;VIII&#x7b49;&#x6cbb;&#x7597;&#x540e;&#xff0c;&#x51dd;&#x8840;&#x529f;&#x80fd;&#x3001;FVIII&#xa789;C&#x6539;&#x5584;&#xff0c;FVIII&#x6291;&#x5236;&#x7269;(-)&#xff0c;&#x672a;&#x53d1;&#x73b0;&#x4e25;&#x91cd;&#x4e0d;&#x826f;&#x53cd;&#x5e94;&#x3002;&#x968f;&#x8bbf;5&#x5e74;&#xff0c;&#x75c5;&#x60c5;&#x7a33;&#x5b9a;&#xff0c;&#x65e0;&#x518d;&#x51fa;&#x8840;&#x3002;SLE&#x51fa;&#x73b0;&#x51dd;&#x8840;&#x529f;&#x80fd;&#x969c;&#x788d;&#xff0c;&#x5c24;&#x5176;&#x662f;&#x5b64;&#x7acb;&#x6027;APTT&#x5ef6;&#x957f;&#xff0c;&#x9700;&#x6ce8;&#x610f;&#x6392;&#x67e5;AHA&#xff0c;&#x7cd6;&#x76ae;&#x8d28;&#x6fc0;&#x7d20;&#x8054;&#x5408;&#x514d;&#x75ab;&#x6291;&#x5236;&#x5242;&#x7597;&#x6548;&#x4e0d;&#x4f73;&#x65f6;&#xff0c;&#x53ef;&#x5c1d;&#x8bd5;&#x8054;&#x5408;&#x4f7f;&#x7528;&#x5229;&#x59a5;&#x6614;&#x5355;&#x6297;&#x3002;.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">acquired hemophilia</Keyword><Keyword MajorTopicYN="N">rituximab</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>7</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>4</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>4</Day><Hour>5</Hour><Minute>29</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37539582</ArticleId><ArticleId IdType="doi">10.11817/j.issn.1672-7347.2023.220440</ArticleId><ArticleId IdType="pii">1672-7347(2023)05-0789-06</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>&#x4e2d;&#x534e;&#x533b;&#x5b66;&#x4f1a;&#x8840;&#x6db2;&#x5b66;&#x5206;&#x4f1a;&#x8840;&#x6813;&#x4e0e;&#x6b62;&#x8840;&#x5b66;&#x7ec4;, &#x4e2d;&#x56fd;&#x8840;&#x53cb;&#x75c5;&#x534f;&#x4f5c;&#x7ec4;. &#x83b7;&#x5f97;&#x6027;&#x8840;&#x53cb;&#x75c5;A&#x8bca;&#x65ad;&#x4e0e;&#x6cbb;&#x7597;&#x4e2d;&#x56fd;&#x6307;&#x5357;(2021&#x5e74;&#x7248;)[J]. &#x4e2d;&#x534e;&#x8840;&#x6db2;&#x5b66;&#x6742;&#x5fd7;, 2021, 42(10): 793- 799. https://doi.org/10.3760/cma.j.issn.0253-2727.2021.10.001.</Citation></Reference><Reference><Citation>Sakalli HEB, Matrane W, Hamzaoui ZE, et al. Acquired hemophilia A: Three cases and review of the literature[J]. Clin Lab, 2019, 65(9): 1745- 1750. https://doi.org/10.7754/Clin.Lab.2019.190140.</Citation></Reference><Reference><Citation>Green D, Lechner KA. A survey of 215 non-hemophilic patients with inhibitors to Factor VIII[J]. Thromb Haemost, 1981, 45(3): 200- 203. https://doi.org/10.1055/s-0038-1650169.</Citation></Reference><Reference><Citation>Knoebl P, Marco P, Baudo F, et al. Demographic and clinical data in acquired hemophilia A: Results from the European Acquired Haemophilia Registry (EACH2)[J]. J Thromb Haemost, 2012, 10(4): 622- 631. https://doi.org/10.1111/j.1538-7836.2012.04654.x.</Citation></Reference><Reference><Citation>Chai-Adisaksopha C, Rattarittamrong E, Norasetthada L, et al. Younger age at presentation of acquired haemophilia A in Asian countries: a single-centre study and systematic review[J/OL]. Haemophilia, 2014, 20(3): e205- e210[ 2022-08-30]. https://pubmed.ncbi.nlm.nih.gov/24847520.</Citation></Reference><Reference><Citation>Collins PW, Hirsch S, Baglin TP, et al. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors&#x2019; Organisation[J]. Blood, 2007, 109(5): 1870- 1877. https://doi.org/10.1182/blood-2006-06-029850.</Citation></Reference><Reference><Citation>Bitting RL, Bent S, Li Y, et al. The prognosis and treatment of acquired hemophilia: a systematic review and meta-analysis[J]. Blood Coagul Fibrinolysis, 2009, 20(7): 517- 523. https://doi.org/10.1097/MBC.0b013e32832ca388.</Citation></Reference><Reference><Citation>O&#x2019;Connor CR. Systematic review of the presentation of coagulation factor VIII inhibitors in rheumatic diseases: A potential cause of life-threatening hemorrhage[J]. Semin Arthritis Rheum, 2015, 44(6): 695- 709. https://doi.org/10.1016/j.semarthrit.2014.11.008.</Citation></Reference><Reference><Citation>Pai M. Acquired hemophilia A[J]. Hematol Oncol Clin North Am, 2021, 35(6): 1131- 1142. https://doi.org/10.1016/j.hoc.2021. 07.007.</Citation></Reference><Reference><Citation>Mazzucconi MG, Baldacci E, Ferretti A, et al. Acquired haemophilia A: An intriguing disease[J/OL]. Mediterr J Hematol Infect Dis, 2020, 12(1): e 2020045[ 2022-08-30]. https:// pubmed.ncbi.nlm.nih.gov/32670523.</Citation></Reference><Reference><Citation>Manikkan AT. Factor X deficiency: an uncommon presentation of AL amyloidosis [J]. Ups J Med Sci, 2012, 117(4): 457- 459. https://doi.org/10.3109/03009734.2012.690457.</Citation></Reference><Reference><Citation>Fulcher CA, de Graaf Mahoney S, Roberts JR, et al. Localization of human factor FVIII inhibitor epitopes to two polypeptide fragments[J]. Proc Natl Acad Sci USA, 1985, 82(22): 7728- 7732. https://doi.org/10.1073/pnas.82.22.7728.</Citation></Reference><Reference><Citation>Fulcher CA, de Graaf Mahoney S, Zimmerman TS. FVIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting[J]. Blood, 1987, 69(5): 1475- 1480. https://doi.org/10.1182/blood.V69.5.1475.1475.</Citation></Reference><Reference><Citation>Kruse-Jarres R, St-Louis J, Greist A, et al. Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A[J]. Haemophilia, 2015, 21(2): 162- 170. https://doi.org/10.1111/hae.12627.</Citation></Reference><Reference><Citation>Hay CR, Negrier C, Ludlam CA. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicentre study[J]. Thromb Haemost, 1997, 78(6): 1463- 1467.</Citation></Reference><Reference><Citation>Negrier C, Goudemand J, Sultan Y, et al. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors[J]. Thromb Haemost, 1997, 77(6): 1113- 1119. https://doi.org/10.1055/s-0038-1656122.</Citation></Reference><Reference><Citation>Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, et al. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors[J]. Br J Haematol, 2003, 121(1): 21- 35. https://doi.org/10.1046/j.1365-2141.2003.04162.x.</Citation></Reference><Reference><Citation>Remmington T, Smith S. Rituximab for eradicating inhibitors in people with acquired haemophilia A [J]. Cochrane Database Syst Rev, 2021, 8(8): CD011907. https://doi.org/10.1002/14651858.CD011907.pub3.</Citation></Reference><Reference><Citation>Tiede A, Collins P, Knoebl P, et al. International recommendations on the diagnosis and treatment of acquired hemophilia A[J]. Haematologica, 2020, 105(7): 1791- 1801. https://doi.org/10.3324/haematol.2019.230771.</Citation></Reference><Reference><Citation>Mingot-Castellano ME, Pardos-Gea J, Haya S, et al. Management of acquired hemophilia A: results from the Spanish registry[J]. Blood Adv, 2021, 5(19): 3821- 3829. https://doi.org/10.1182/bloodadvances.2021004626.</Citation></Reference><Reference><Citation>&#x6768;&#x8273;&#x4e3d;, &#x4e54;&#x9e4f;&#x71d5;, &#x9648;&#x6631;, &#x7b49;. &#x7ed3;&#x7f14;&#x7ec4;&#x7ec7;&#x75c5;&#x5408;&#x5e76;&#x83b7;&#x5f97;&#x6027;&#x8840;&#x53cb;&#x75c5;&#x7532;&#x516b;&#x4f8b;&#x4e34;&#x5e8a;&#x5206;&#x6790;[J]. &#x4e2d;&#x534e;&#x98ce;&#x6e7f;&#x75c5;&#x5b66;&#x6742;&#x5fd7;, 2019, 23(4): 259- 262. https://doi.org/10.3760/cma.j.issn.1007-7480.2019.04.008.</Citation></Reference><Reference><Citation>Collins PW. Treatment of acquired hemophilia A[J]. J Thromb Haemost, 2007, 5(5): 893- 900. https://doi.org/10.1111/j.1538-7836.2007.02433.x.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>